OS Therapies Incorporated (OSTX) News
Follow OS Therapies Incorporated (OSTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
OS Therapies Raises About $7.2 Million From Warrant Exercise
OS Therapies closed an initial warrant exercise inducement, raising approximately $7.2 million gross from 5,517,253 shares at $1.30 and issuing new warrants at $1.40. It also accrued $7.0 million in U.K. R&D tax credits,
EQUITY | Oct 19, 2026, 12:34 PM UTC
H
OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine Osteosarcoma
OS Therapies, Inc. (NYSE: OSTX ) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that its wholly-owned animal health subsidiary, OSAH received fe
LIVE | Oct 07, 2026, 12:40 PM UTC
M
OS Therapies Reports 72.7% 3-Year OS in Osteosarcoma Trial
OS Therapies reported that OST-HER2 demonstrated a 72.7% 3-year overall survival rate in its Phase 2b pulmonary metastatic osteosarcoma trial. This compares to 45.8% in historical controls. The company plans to initiate
EQUITY | Oct 06, 2026, 12:33 PM UTC
H
OS Therapies reports statistically significant 3-year OS benefit in Phase 2b
OS Therapies said Phase 2b results in herlystic(TM)-treated pulmonary metastatic osteosarcoma patients showed a statistically significant final three-year overall survival benefit.
EQUITY | Oct 06, 2026, 12:31 PM UTC
L
OS Therapies, Inc. (OSTX) WHO Clears 'Herlystic'; UK Filing Next, Orbis Path Planned
OS Therapies received WHO approval of 'Herlystic' for OST-HER2 and plans to file first with the U.K. MHRA under Project Orbis, followed by FDA, EMA and TGA. FDA BLA is targeted under Accelerated Approval after final 3-ye
REGULATION | Sep 24, 2026, 12:23 PM UTC
L
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
New York, New York and Rockville, Maryland--(. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, t
NEWS | Sep 24, 2026, 12:22 PM UTC
L
OS Therapies achieves incremental FDA alignment for OST-HER2
OS Therapies says it has achieved incremental alignment with the FDA and accepted an MHRA Project Orbis invitation for its OST-HER2 metastatic osteosarcoma program.
REGULATION | Sep 17, 2026, 10:01 AM UTC
L
OS Therapies, Inc. (AMEX:OSTX) Aligned With MHRA/EMA on CMAA; Phase 3 To Start in Q4 2026
OS Therapies achieved full alignment with the UK MHRA and EU EMA on its Conditional Marketing Authorisation plans and Phase 3 design for OST-HER2, expects CMAA filing in coming weeks, and intends to start the confirmator
NEWS | Sep 15, 2026, 11:53 AM UTC
L
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
New York, New York and Rockville, Maryland--(. - September 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, t
NEWS | Sep 15, 2026, 11:51 AM UTC
M
OS Therapies reports statistically significant interim 3-year OS benefit
OS Therapies (OSTX) announced a statistically significant benefit for OST-HER2-treated patients in interim 3-year overall survival analysis from its Phase 2b pulmonary metastatic osteosarcoma trial.
EQUITY | Sep 08, 2026, 10:06 AM UTC
L
OS Therapies updates OST-HER2 metastatic osteosarcoma program
OS Therapies, Inc. said it provided an update on its OST-HER2 metastatic osteosarcoma program and announced upcoming conference attendance by its management team and business development advisors.
EQUITY | Sep 02, 2026, 11:26 AM UTC
M
OS Therapies reports Q2 2026 financials; shares business and regulatory updates
OS Therapies (OSTX) reports its second-quarter 2026 financials and provides accompanying business and regulatory updates.
REGULATION | Aug 17, 2026, 11:50 AM UTC
L
OS Therapies Expects Phase 3 Study For The OST-HER2 Metastatic Osteosarcoma Program To Begin Near End Of Q3 2026
OS Therapies, Inc. (NYSE: OSTX ) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provides a third quarter 2026 corporate outlook. The outlook focuses on up
FX | Jul 06, 2026, 01:10 PM UTC
L
OS Therapies Third Quarter 2026 Corporate Outlook
Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market access
REGULATION | Jul 06, 2026, 01:01 PM UTC
H
OS Therapies shares are trading lower. The company requested a Type B Meeting to follow up on FDA guidance for its OST‑HER2 BLA, submitted b
OS Therapies shares are trading lower. The company requested a Type B Meeting to follow up on FDA guidance for its OST‑HER2 BLA, submitted biomarker data to the BEST program, added a synthetic control arm, and sought Rol
EARNINGS | Jun 30, 2026, 05:58 PM UTC
H
OS Therapies Requests FDA Type B Meeting To Review Its 2.5-Year OST-HER2 Overall Survival Data And To Confirm Alignment That 3-year Overall
OS Therapies, Inc. (NYSE: OSTX ) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provided regulatory update on the Company's interactions with the U.S. Foo
EARNINGS | Jun 30, 2026, 11:45 AM UTC
L
OSTX Publishes Clinical Trial Data
OSTX OS Animal Health announces peer-reviewed publication of clinical trial data for OST-HER2 plus palliative radiation as frontline treatment in canine osteosarcoma
EQUITY | Jun 26, 2026, 11:47 AM UTC